Sanofi in yet another emerging-market buyout

Sanofi-Aventis is on a dealmaking roll. The company is set to acquire Brazilian generics maker Medley, according to a local paper, for $670 million. The French pharma just snapped up Laboratorios Kendrick, a Mexican drugmaker, and not too long ago completed its buyout of Czech generics leader Zentiva. Plus, Sanofi had been on the hunt for India's Piramal until that company priced itself out of the deal.

All these companies are a.) located and operating in emerging markets, and b.) big into copycat meds. So, each makes two diversification moves for the price of one. All to the good for new CEO Chris Viehbacher's (photo) stated goal of broadening Sanofi's focus.

Don't expect the Medley buy--which is expected to close in about two weeks--to be Sanofi's last, either. Viehbacher has assembled an acquisition war chest, and he's pledged to deliver lots of new drug candidates via licensing and/or buyouts.

- read the Dow Jones news

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.